Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid-β peptide via hydrophobic interactions

Histidine Targeting Heterobimetallic Ruthenium(II)–Gold(I) Complexes

(2019) Lucinda K. Batchelor et al.   INORGANIC CHEMISTRY

NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry

(2019) Enzo Alessio et al.   MOLECULES

Modulation of β-amyloid aggregation by graphene quantum dots

(2019) Changliang Liu et al.   Royal Society Open Science

Modification of Aβ Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes

(2019) Luiza M. F. Gomes et al.   Frontiers in Chemistry

Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents

(2018) Mousumi Pal et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Amyloid β-targeted metal complexes for potential applications in Alzheimer's disease

(2018) Hao Liu et al.   Future Medicinal Chemistry

Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

(2016) Enzo Alessio   EUROPEAN JOURNAL OF INORGANIC CHEMISTRY

Zinc(II) Binding Site to the Amyloid-β Peptide: Insights from Spectroscopic Studies with a Wide Series of Modified Peptides

(2016) Bruno Alies et al.   INORGANIC CHEMISTRY

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism

(2016) Aleksandar Bijelic et al.   JOURNAL OF MEDICINAL CHEMISTRY

Albumin binding and ligand-exchange processes of the Ru(iii) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy

(2015) Michael I. Webb et al.   DALTON TRANSACTIONS

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

(2014) Suzanne Leijen et al.   INVESTIGATIONAL NEW DRUGS

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

(2014) Robert Trondl et al.   Chemical Science

Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-β peptide

(2013) Victor A. Streltsov et al.   CHEMICAL COMMUNICATIONS

Increasing the Bioavailability of RuIIIAnticancer Complexes through Hydrophobic Albumin Interactions

(2013) Michael I. Webb et al.   CHEMISTRY-A EUROPEAN JOURNAL

EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds

(2013) Michael I. Webb et al.   Metallomics

Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult

(2013) William I. Rosenblum   NEUROBIOLOGY OF AGING

Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex

(2013) Luigi Messori et al.   ACS Medicinal Chemistry Letters

Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases)

(2012) Henryk Kozlowski et al.   COORDINATION CHEMISTRY REVIEWS

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells

(2012) Jade B. Aitken et al.   Metallomics

Identification of [PtCl2(phen)] Binding Modes in Amyloid-β Peptide and the Mechanism of Aggregation Inhibition

(2011) Guolin Ma et al.   CHEMISTRY-A EUROPEAN JOURNAL

Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin

(2011) Michael I. Webb et al.   DALTON TRANSACTIONS

Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin

(2011) Michael I. Webb et al.   INORGANIC CHEMISTRY

Aluminum, copper, iron and zinc differentially alter amyloid-Aβ1–42 aggregation and toxicity

(2011) Silvia Bolognin et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Cu(II) Mediates Kinetically Distinct, Non-amyloidogenic Aggregation of Amyloid-β Peptides

(2011) Jeppe T. Pedersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular mechanism of Thioflavin-T binding to amyloid fibrils

(2010) Matthew Biancalana et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

fac-{Ru(CO)3}2+Selectively Targets the Histidine Residues of the β-Amyloid Peptide 1-28. Implications for New Alzheimer's Disease Treatments Based on Ruthenium Complexes

(2010) Daniela Valensin et al.   INORGANIC CHEMISTRY

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

(2010) Petra Heffeter et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Preparation and characterization of toxic Aβ aggregates for structural and functional studies in Alzheimer's disease research

(2010) Asad Jan et al.   Nature Protocols

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

(2009) Frederike Lentz et al.   ANTI-CANCER DRUGS

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR

(2009) Naniye Cetinbas et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

The Aging Brain

(2008) Bruce A. Yankner et al.   Annual Review of Pathology-Mechanisms of Disease

KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

(2008) Christian G. Hartinger et al.   CHEMISTRY & BIODIVERSITY

Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes

(2008) By Jan Reedijk  

Platinum-based inhibitors of amyloid-  as therapeutic agents for Alzheimer's disease

(2008) K. J. Barnham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA